Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Impact of gut mycobiota on outcomes after allo-HSCT

Mohamad Mohty • 7 Dec 2019
ASH 2019
General

Alterations of gut bacterial microbiota composition (mycobiota) have been associated with outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT), however the impact of the gut mycobiota is still unknown in the allo-HSCT setting. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses a study that examined the role of fecal mycobiota in patients undergoing allo-HSCT. Prof. Mohty highlights the low fungal diversity in allo-HSCT patients and the future perspectives for this novel field of investigation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Mohamad Mohty

CERVINO trial results and the potential role of etentamig in multiple myeloma
1:19
CERVINO trial results and the potential role of etentamig in multiple myeloma
Mohamad Mohty • 24 Sep 2026
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
7:00
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
Mohamad Mohty • 24 Sep 2026
Transitioning bispecifics into community care for myeloma: recently published guidelines
5:44
Transitioning bispecifics into community care for myeloma: recently published guidelines
Mohamad Mohty • 13 Jun 2026
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
8:13
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Mohamad Mohty • 15 May 2026

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals